Sulzberger Capital Advisors Inc. Invests $453,000 in Johnson & Johnson (NYSE:JNJ)

Sulzberger Capital Advisors Inc. purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 3,130 shares of the company's stock, valued at approximately $453,000.

A number of other hedge funds also recently bought and sold shares of JNJ. Principal Financial Group Inc. raised its position in shares of Johnson & Johnson by 10.5% during the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock valued at $562,723,000 after buying an additional 329,473 shares during the period. Invst LLC raised its position in Johnson & Johnson by 394.0% in the third quarter. Invst LLC now owns 10,290 shares of the company's stock valued at $1,668,000 after purchasing an additional 8,207 shares during the period. McIlrath & Eck LLC lifted its stake in shares of Johnson & Johnson by 10.7% in the 3rd quarter. McIlrath & Eck LLC now owns 2,892 shares of the company's stock valued at $469,000 after purchasing an additional 279 shares during the last quarter. Passumpsic Savings Bank acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $262,000. Finally, Te Ahumairangi Investment Management Ltd raised its holdings in Johnson & Johnson by 10.1% in the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 50,765 shares of the company's stock valued at $8,180,000 after buying an additional 4,640 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Up 1.1 %

Shares of JNJ traded up $1.63 during midday trading on Friday, reaching $156.09. The stock had a trading volume of 5,973,317 shares, compared to its average volume of 7,879,761. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company's fifty day simple moving average is $158.85 and its two-hundred day simple moving average is $154.67. The company has a market cap of $375.56 billion, a price-to-earnings ratio of 23.47, a PEG ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.33%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on JNJ shares. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Bank of America dropped their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. Argus upgraded Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Wells Fargo & Company dropped their price objective on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Finally, Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $171.82.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.